Mitomycin c is one of 294 small molecule programs targeting Glaucoma. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
350 competitors in Treatment
Mitomycin c
Biltricide
Dexilant
Alfenta
Niclocide
Minipress
Theo-Dur
Levulan
Aurlumyn
Lotemax
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details